Behind Zeneca's glamour rating

THE INVESTMENT COLUMN

Zeneca has been the object of so much takeover speculation recently that nobody seemed terribly interested in interim figures yesterday from the former ICI drugs arm. That is a mistake, because if the company's robust rebuttal of bid talk is to be believed, the market will have to start valuing Zeneca on fundamentals once more.

The bid story is unlikely to go away as long as the drugs industry continues to consolidate at its current rapid rate. Zeneca is plainly still attractive, if expensive, and Roche, the rumoured predator, is perhaps the only company with the firepower and the acquisition history to be a serious contender.

But pounds 15bn, which is what it would probably have to pay to secure control of Zeneca, would be a massive undertaking even for Roche. It would be paying a pharmaceutical multiple for a big chunk of much lower-margin agrochemical and speciality chemical earnings. Perhaps most importantly, David Barnes, chief executive, has made things quite clear - Zeneca and Roche are not talking.

How then do Zeneca's figures and its relatively fancy rating stack up together? Yesterday's half-time profits, up 44 per cent to pounds 506m, were flattered by last year's pounds 100m exceptional charge, but even on a comparable basis, there was a 12 per cent improvement. Earnings per share, up 41 per cent to 35.8p, allowed a 0.5p rise in the dividend to 11.25p.

Zeneca's return on sales, at 20.4 per cent was a record, as were sales from the core drugs arm, which breached pounds 1bn for the first time in a six- month period. The underlying business is as strong as ever despite cautious hints about second-half margins, expected to be squeezed by the costs of promoting new treatments. Analysts describe Zeneca as the sector's lowest-risk business.

That reflects its solid new drugs pipeline, which includes four new treatments for cancer, an innovative pill for asthma and a schizophrenia drug. It is also an appreciation of the recent Salick acquisition, which took Zeneca into managed cancer care for the first time.

Salick owns specialised cancer clinics in the US and represents the future of health care in America and, probably, Europe as well. Giving Zeneca exposure to the growing market for cancer treatment, even without new drugs, it is a sensible diversification and, on the basis of a 50 per cent initial stake, a relatively low-risk venture.

Profits are forecast to grow from an underlying pounds 797m last year to pounds 860m this time and pounds 960m in 1996. That puts the shares, down 23p to 1,097p yesterday, on a prospective price-earnings ratio, 18 months out, of 16. On a sizeable premium to Glaxo's 13.5 times multiple and a slightly better rating even than US stocks in the sector, the shares still appear to reflect a bit of bid froth. While a takeover remains an outside chance they probably won't fall far, but equally the upside looks limited.

Time for Shell to grit its teeth

Shares in Shell were suffering yesterday from the problem all cyclical companies face once the market sees confirmation of an earnings plateau ahead. Results may be impressive but the City always looks forward and the 15p fall to 759p reflected its concerns.

Interim results were exceptionally buoyant, with net income in the second quarter up 90 per cent to pounds 1.28bn. Admittedly, the number was flattered by an pounds 80m special credit from sale of copper interests in Chile and a pounds 77m currency gain. But chemicals continued their much-improved performance, making a pounds 313m profit instead of a pounds 41m loss a year earlier.

The comparison is with the last of the bad quarters before the recovery began, and the latest quarter includes consolidation for the first time of new chemical subsidiary Montell, so the underlying trend compared with the immediately preceding quarter is rather flat. But there was little to complain about, especially as firmer oil prices also boosted exploration and production profits 47 per cent.

The real difficulty was with Shell's comments on the oil market and the rather gloomier than expected forecast for chemicals, the heart of Shell's recovery over the past year.

Oil prices remained strong until April but fell sharply at the end of the second quarter, with Brent now trading at about $16 a barrel and expected to stay around that level for the current quarter.

Ignoring minor shades of opinion, there was little here that was not built into the market's expectations. But one problem will continue to undermine Shell's shares relative to the rest of the oil sector.

Shell trades at a 10 per cent premium to the market. BP, which has much better dividend growth prospects because it starts from a lower point, trades marginally below. The whole sector is at risk from weaker oil and chemical markets over the next couple of years, and Shell more so than its peers.

Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
musicOfficial chart could be moved to accommodate Friday international release day
Sport
Wes Brown is sent-off
football
News
i100
Sport
Italy celebrate scoring their second try
six nations
Sport
Glenn Murray celebrates scoring against West Ham
footballWest Ham 1 Crystal Palace 3
Arts and Entertainment
Drake continues to tease ahead of the release of his new album
music
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: HR Benefits Manager

£40000 - £50000 per annum + pro rata: SThree: SThree Group have been well esta...

Recruitment Genius: Office Manager / Financial Services

£30000 - £37000 per annum: Recruitment Genius: Established in 1999, a highly r...

Jemma Gent: Year End Accountant

£250-£300 Day Rate: Jemma Gent: Are you a qualified accountant with strong exp...

Jemma Gent: Management Accountant

£230 - £260 Day Rate: Jemma Gent: Do you want to stamp your footprint in histo...

Day In a Page

Chelsea vs Tottenham: Harry Kane was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope

Harry Kane interview

The striker was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope
The Last Word: For the good of the game: why on earth don’t we leave Fifa?

Michael Calvin's Last Word

For the good of the game: why on earth don’t we leave Fifa?
HIV pill: Scientists hail discovery of 'game-changer' that cuts the risk of infection among gay men by 86%

Scientists hail daily pill that protects against HIV infection

Breakthrough in battle against global scourge – but will the NHS pay for it?
How we must adjust our lifestyles to nature: Welcome to the 'Anthropocene', the human epoch

Time to play God

Welcome to the 'Anthropocene', the human epoch where we may need to redefine nature itself
MacGyver returns, but with a difference: Handyman hero of classic 1980s TV series to be recast as a woman

MacGyver returns, but with a difference

Handyman hero of classic 1980s TV series to be recast as a woman
Tunnel renaissance: Why cities are hiding roads down in the ground

Tunnel renaissance

Why cities are hiding roads underground
'Backstreet Boys - Show 'Em What You're Made Of': An affectionate look at five middle-aged men

Boys to men

The Backstreet Boys might be middle-aged, married and have dodgy knees, but a heartfelt documentary reveals they’re not going gently into pop’s good night
Crufts 2015: Should foreign dogs be allowed to compete?

Crufts 2015

Should foreign dogs be allowed to compete?
10 best projectors

How to make your home cinema more cinematic: 10 best projectors

Want to recreate the big-screen experience in your sitting room? IndyBest sizes up gadgets to form your film-watching
Manchester City 1 Barcelona 2 player ratings: Luis Suarez? Lionel Messi? Joe Hart? Who was the star man?

Manchester City vs Barcelona player ratings

Luis Suarez? Lionel Messi? Joe Hart? Who was the star man at the Etihad?
Arsenal vs Monaco: Monaco - the making of Gunners' manager Arsene Wenger

Monaco: the making of Wenger

Jack Pitt-Brooke speaks to former players and learns the Frenchman’s man-management has always been one of his best skills
Cricket World Cup 2015: Chris Gayle - the West Indies' enigma lives up to his reputation

Chris Gayle: The West Indies' enigma

Some said the game's eternal rebel was washed up. As ever, he proved he writes the scripts by producing a blistering World Cup innings
In Ukraine a dark world of hybrid warfare and murky loyalties prevails

In Ukraine a dark world of hybrid warfare

This war in the shadows has been going on since the fall of Mr Yanukovych
'Birdman' and 'Bullets Over Broadway': Homage or plagiarism?

Homage or plagiarism?

'Birdman' shares much DNA with Woody Allen's 'Bullets Over Broadway'
Broadchurch ends as damp squib not even David Tennant can revive

A damp squib not even David Tennant can revive

Broadchurch, Series 2 finale, review